Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Roesch

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2025
Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathwaysSejal Chopra, Jaya Shukla, Priyavrat Purohit, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Targeting CXCR4/CXCL12 axis via [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub> with CXCR4 antagonist in triple-negative breast cancerGuangfa Bao, Ziqiang Wang, Luoxia Liu, et al.
Clinical Nuclear Medicine|January 6, 2025
Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68 Ga-DATA 5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors PatientsSanjana Ballal, Parvind Sheokand, Madhav P Yadav, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 10, 2022
Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention timeEuy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, et al.
Cancers|March 29, 2023
Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in RadiotheranosticsMarcel Martin, Sanjana Ballal, Madhav Prasad Yadav, et al.
Clinical Nuclear Medicine|February 2, 2023
68 Ga-DOTA.SA.FAPI as a Potential, Noninvasive Diagnostic Probe for Recurrent and Metastatic Adrenocortical Carcinoma : A Head-to-Head Comparison With 18F-FDGSejal Chopra, Rama Walia, Yamini Mathur, et al.
Academic Radiology|January 17, 2024
<sup>68</sup>Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with <sup>18</sup>F-FDGSejal Chopra, Yamini Mathur, Frank Roesch, et al.
Thyroid : Official Journal of the American Thyroid Association|October 13, 2021
Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot StudySanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2011
Characterisation of [¹¹C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporterPatrick J Riss, Jacob M Hooker, Colleen Shea, et al.
Nuklearmedizin. Nuclear Medicine|July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumoursBarbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Nuclear Medicine and Molecular Imaging|March 22, 2025
Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathwaysSejal Chopra, Jaya Shukla, Priyavrat Purohit, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Targeting CXCR4/CXCL12 axis via [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub> with CXCR4 antagonist in triple-negative breast cancerGuangfa Bao, Ziqiang Wang, Luoxia Liu, et al.
Clinical Nuclear Medicine|January 6, 2025
Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68 Ga-DATA 5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors PatientsSanjana Ballal, Parvind Sheokand, Madhav P Yadav, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 10, 2022
Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention timeEuy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, et al.
Cancers|March 29, 2023
Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in RadiotheranosticsMarcel Martin, Sanjana Ballal, Madhav Prasad Yadav, et al.
Clinical Nuclear Medicine|February 2, 2023
68 Ga-DOTA.SA.FAPI as a Potential, Noninvasive Diagnostic Probe for Recurrent and Metastatic Adrenocortical Carcinoma : A Head-to-Head Comparison With 18F-FDGSejal Chopra, Rama Walia, Yamini Mathur, et al.
Academic Radiology|January 17, 2024
<sup>68</sup>Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with <sup>18</sup>F-FDGSejal Chopra, Yamini Mathur, Frank Roesch, et al.
Thyroid : Official Journal of the American Thyroid Association|October 13, 2021
Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot StudySanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2011
Characterisation of [¹¹C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporterPatrick J Riss, Jacob M Hooker, Colleen Shea, et al.
Nuklearmedizin. Nuclear Medicine|July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumoursBarbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Pageof 7